FindTrial
Sign In

Efficacy and safety of hypothermia and erythropoietin for neonatal hypoxic-ischemic encephalopathy

Efficacy and safety of hypothermia and erythropoietin for neonatal hypoxic-ischemic encephalopathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004532
Enrollment
Unknown
Registered
2014-04-18
Start date
2014-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal hypoxic-ischemic encephalopathy

Interventions

Intervention group:hypothermia and erythropoietin
control:hypothermia

Sponsors

Children's Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Gestational age =36 weeks; an Apgar score =3 at 1 minute and =5 at 5 minutes, and/or cord blood gas pH <7.0 or base deficit =16 mmol/L, and/or need for resuscitation or ventilation at 5 minutes of age at least.

Exclusion criteria

Exclusion criteria: 1. Major congenital abnormalities; 2. Infection (rupture of membrance >18h or maternal fever >38 or amniotic fluid foul smell); 3. Other encephalopathy (neonatal stroke, CNS abnormality, intracranial hemorrhage diagnosed by CT or head ultrasonography); 4. Severe anemia (Hb <120g/L).

Design outcomes

Primary

MeasureTime frame
mortality;The incidence of severe disability;—

Countries

China

Contacts

Public ContactWenhao Zhou

Children's Hospital of Fudan University

zwhchfu@126.com+86 13621830506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026